Summit Therapeutics Q2 net loss narrows on lower stock compensation
SMMT•FDA and trial timeline outlook
Summit expects an FDA decision on the ivonescimab BLA by Nov. 14, 2026.
The company anticipates HARMONi-3 squamous cohort PFS events in the second half of 2026 and non-squamous events in the first half of 2027.
Summit also plans further expansion of global Phase III ivonescimab studies in additional tumor types.
Quarterly figures and analyst view
| Metric | Actual |
|---|---|
| Q2 loss per share | $0.28 |
| Q2 net loss | $215.70 million |
| Q2 operating expenses | $220.50 million |
The current average analyst rating on the shares is buy, with 11 strong buy or buy, 5 hold, and 2 sell or strong sell recommendations.
The average consensus recommendation for the biotechnology and medical research peer group is buy.
Wall Street's median 12-month price target for Summit Therapeutics Inc is $33.00, about 123.9% above its July 22 closing price of .
